Ganga Pharmaceuticals Ltd
Ganga Pharmaceuticals: Q2 FY27 Net Profit Rs. 186 Lakhs for Half Year Ended Sep 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 04:40 PM IST · BSE ID: 291127bb-0926-4299-91e8-c85e29c42043
View Original BSE Filing (PDF)
💡
In Simple Terms
Ganga Pharmaceuticals' profits were Rs. 186 Lakhs for the six months ending September 2026, as approved by its Board.
🤖 AI Summary
- Ganga Pharmaceuticals reported a net profit of Rs. 186 Lakhs for the half year ended September 30, 2026.
- Revenue from operations was Rs. 141.63 Lakhs for the half year ended September 30, 2026.
- Total expenses reached Rs. 152.76 Lakhs for the half year ended September 30, 2026.
- Basic Earnings Per Share (EPS) stood at Rs. 0.03 for the half year ended September 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Net Profit for half year ended 30 Sep 2026
186 Lakhs
Revenue from operations for half year ended 30 Sep 2026
141.63 Lakhs
Total Income for half year ended 30 Sep 2026
155.27 Lakhs
Basic Earnings per equity share for half year ended 30 Sep 2026
0.03 Rs.
Net cash from operating activities for half year ended 30 Sep 2026
-15.09 Lakhs
Cash and cash equivalents as at 30 Sep 2026
2.17 Lakhs
🏢 How This Affects the Company
Revenue from operations for the half year ended September 30, 2026, was Rs. 141.63 Lakhs, with total income at Rs. 155.27 Lakhs.
Net profit for the half year ended September 30, 2026, was Rs. 186 Lakhs, impacting overall earnings. Cash and cash equivalents decreased from Rs. 5.82 Lakhs at March 31, 2026, to Rs. 2.17 Lakhs at September 30, 2026.
The cost of materials consumed was Rs. 80.42 Lakhs and employee benefit expenses were Rs. 2.72 Lakhs for the half year.
Net cash from operating activities for the half year was a negative Rs. 15.09 Lakhs, indicating cash outflow from core operations.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the decline in net profit to Rs. 186 Lakhs and Basic EPS to Rs. 0.03.
🔍
Management Signal
The Board's approval of the unaudited financial results and the limited review report indicates a commitment to regulatory disclosure requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for improvements in net profit and cash flow.
Any further disclosures on operational efficiencies or cost management initiatives.
Future updates on revenue diversification or growth strategies.
MEDIUM RISK
Decline in net profit and negative cash flow from operations for the half year.
💡 Investor Takeaway
Ganga Pharmaceuticals reported a net profit of Rs. 186 Lakhs for the half year ended September 30, 2026. This is a decrease from Rs. 550 Lakhs reported for the half year ended September 30, 2025. Revenue from operations for the period was Rs. 141.63 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Total income for the half year ended September 30, 2026, increased to Rs. 155.27 Lakhs from Rs. 46.91 Lakhs in the prior comparable period.
- Share capital remained stable at Rs. 591.15 Lakhs as of September 30, 2026, matching March 31, 2026 figures.
⚠️ Concerns
- Net Profit for the half year ended September 30, 2026, was Rs. 186 Lakhs, a decline from Rs. 550 Lakhs in the prior comparable period.
- Cash and cash equivalents decreased from Rs. 5.82 Lakhs at March 31, 2026, to Rs. 2.17 Lakhs as of September 30, 2026.
📅 Company Track Record
Previous filings indicated Ganga Pharmaceuticals' net profit for the half year ended September 2026 was down to Rs. 186 Lakhs. This filing provides the detailed breakdown for that period, showing a decline compared to Rs. 550 Lakhs in the prior comparable period.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Ganga Pharmaceuticals' net profit for the half year ended September 30, 2026?
Ganga Pharmaceuticals reported a net profit of Rs. 186 Lakhs for the half year ended September 30, 2026.
What was Ganga Pharmaceuticals' revenue from operations for Q2 FY27?
The company's revenue from operations for the half year ended September 30, 2026 (Q2 FY27) was Rs. 141.63 Lakhs.
How did Ganga Pharmaceuticals' cash position change as of September 30, 2026?
Cash and cash equivalents decreased to Rs. 2.17 Lakhs as of September 30, 2026, from Rs. 5.82 Lakhs at March 31, 2026.
What was the Basic Earnings Per Share (EPS) for Ganga Pharmaceuticals for the half year ended September 30, 2026?
The Basic Earnings Per Share (EPS) for Ganga Pharmaceuticals for the half year ended September 30, 2026, was Rs. 0.03.
Questions based on this BSE filing only. For information purposes.